Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial
✍ Scribed by van der Heijde, Désirée ;Han, Chenglong ;DeVlam, Kirt ;Burmester, Gerd ;van den Bosch, Filip ;Williamson, Paul ;Bala, Mohan ;Han, John ;Braun, Jürgen
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 90 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1
## Abstract ## Objective There is increasing evidence that tumor necrosis factor α (TNFα) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFα therapy with etanercept, a 75‐kd recepto